134 related articles for article (PubMed ID: 37861921)
1. Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme.
Kim N; Lee J; Nam DH; Lee JI; Seol HJ; Kong DS; Choi JW; Chong K; Lee WJ; Chang JH; Kang SG; Moon JH; Cho J; Lim DH; Yoon HI
J Neurooncol; 2023 Nov; 165(2):261-268. PubMed ID: 37861921
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Care and Outcomes of Hypofractionated Chemoradiation Versus Conventionally Fractionated Chemoradiation for Glioblastoma in the Elderly Population.
Haque W; Verma V; Butler EB; Teh BS
Am J Clin Oncol; 2018 Feb; 41(2):167-172. PubMed ID: 29369825
[TBL] [Abstract][Full Text] [Related]
5. Effect of a Time Delay for Concomitant Chemoradiation After Surgery for Newly Diagnosed Glioblastoma: A Single-Institution Study with Subgroup Analysis According to the Extent of Tumor Resection.
Ahn S; Park JS; Song JH; Jeun SS; Hong YK
World Neurosurg; 2020 Jan; 133():e640-e645. PubMed ID: 31568907
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
7. Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme.
Zincircioglu SB; Kaplan MA; Isikdogan A; Cil T; Karadayi B; Dirier A; Kucukoner M; Inal A; Yildiz I; Aggil F; Donmez O; Urakci Z; Pekkolay Z; Firat U
J BUON; 2012; 17(1):124-7. PubMed ID: 22517705
[TBL] [Abstract][Full Text] [Related]
8. Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity-score matched analysis.
Sun H; Liu C; Zhang J; Yang G; Han D; Liu T; Huang W; Li B
Radiother Oncol; 2022 Jul; 172():140-146. PubMed ID: 35101460
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.
Lukács G; Tóth Z; Sipos D; Csima M; Hadjiev J; Bajzik G; Cselik Z; Semjén D; Repa I; Kovács Á
Ideggyogy Sz; 2018 Mar; 71(3-04):95-103. PubMed ID: 29889468
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of concurrent conventional chemoradiotherapy versus hypofractionated chemoradiotherapy in newly diagnosed glioblastoma multiforme postoperative patients.
Khatri NK; Kumar HS; Sharma N; Jakhar SL; Dhaka S
J Cancer Res Ther; 2023; 19(5):1126-1130. PubMed ID: 37787273
[TBL] [Abstract][Full Text] [Related]
11. Survival Analysis of Glioblastoma Multiforme.
Witthayanuwat S; Pesee M; Supaadirek C; Supakalin N; Thamronganantasakul K; Krusun S
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2613-2617. PubMed ID: 30256068
[TBL] [Abstract][Full Text] [Related]
12. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
Faustino AC; Viani GA; Hamamura AC
Clinics (Sao Paulo); 2020; 75():e1553. PubMed ID: 32935821
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
14. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
Fiorentino A; Balducci M; De Bonis P; Chiesa S; De Filippo L; Mangiola A; De Rose F; Autorino R; Rinaldi C; Fersino S; Diletto B; Matteucci P; Ciurlia E; Fusco V; Anile C; Valentini V
Am J Clin Oncol; 2015 Feb; 38(1):23-7. PubMed ID: 23388566
[TBL] [Abstract][Full Text] [Related]
15. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
17. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].
Wang XM; Wang L; Wang X; Chen JQ; Li C; Zhang WC; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Han C; Pang QS; Wang P; Sun XC; Zhang KX; Li GF; Li L; Liu ML; Wang YD; Qiao XY; Zhu SC; Zhou ZM; Zhao YD; Xiao ZF
Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):889-896. PubMed ID: 34407597
[No Abstract] [Full Text] [Related]
18. Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China.
Wang Y; Zhang J; Li W; Jiang T; Qi S; Chen Z; Kang J; Huo L; Wang Y; Zhuge Q; Gao G; Wu Y; Feng H; Zhao G; Yang X; Zhao H; Wang Y; Yang H; Kang D; Su J; Li L; Jiang C; Li G; Qiu Y; Wang W; Wang H; Xu Z; Zhang L; Wang R
Future Oncol; 2021 Nov; 17(33):4571-4582. PubMed ID: 34519220
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
Tunthanathip T; Sangkhathat S
Clin Neurol Neurosurg; 2020 Apr; 191():105712. PubMed ID: 32036239
[TBL] [Abstract][Full Text] [Related]
20. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
